Twitter Beğeni Hilesi

🚨Out in JAMA Oncology our effort to determine the association of automatically extracted body composition metrics with #immunotherapy efficacy in patients with metastatic #NSCLC. 👉Skeletal muscle loss & changes in subcutaneous adipose tissue are important dynamic prognostic

The association of automatically extracted body composition metrics with IO efficacy in mNSCLC - Biagio Ricciuti, MD PhD JAMA Oncology Dana-Farber News Tafadzwa L. Chaunzwa João Alessi, MD Alessandro Di Federico, MD Mark Awad oncodaily.com/insight/73659.… #Cancer #CancerResearch #LCSM #NSCLC #OncoDaily #Oncology

Excellent #ASCO24 with colleagues and friends. Proud to be part of both Gustave Roussy and Dana-Farber Thanks to my mentors Benjamin Besse Mark Awad

#BiomarkersAtlas, an ambitious project aiming to integrate clinical records with molecular alterations of NSCLC patients in the real-word Italian scenario.

Couldn’t agree more!! Arushi is talented and compassionate med student. Her work will be instrumental to understanding the correlates of response to #immunotherapy in #NSCLC with STK11/KEAP1/SMARCA4 mutations. Harvard Medical School Dana-Farber. More on this at #WCLC24 IASLC.

Thanks Annals of Oncology for featuring our review on how to optimize the use of #TMB for predicting #ICI efficacy on this month’s cover. ESMO - Eur. Oncology Here we reviewed challenges & opportunities for TMB & immunotherapy focusing on: -Technical limitations 🔬 -Spatial & temporal

Thanks OncoAlert Narjust Florez, MD, FASCO for the opportunity to share our prospective study presented at Best of ASCO as poster presentation Luca Cantini Valeria Cognigni Mariangela Gualtieri Giulia Bruschi rossanaberardi

KEAP and STK11 mutations are a kind of defense mechanism. IO + chemo would be improve that response? Great paper 🔖 jto.org/action/showPdf… Congratulations! Biagio Ricciuti, MD PhD Marina Garassino

🚨Fusion partners and chromosomal breakpoints of oncogenic fusions involving #ALK, #ROS1, #RET and #NTRK1 are not stochastic! Out in Nature Communications our study demonstrating that typical #TK fusions are selected from pools of chromosomal rearrangements by two major determinants:

Congratulations to @danafarber BiagioRicciuti, MD, PhD (Biagio Ricciuti, MD PhD) who is a recipient of the IASLC 2024 Young Investigator Grant for his work: Targeting KRAS amplification as a de novo oncogene driver alteration in non-small cell lung cancer. More▶️ms.spr.ly/6011YfYmB

Honored to receive a 2024 IASLC #YIA. Congrats to all awardees & friends Biagio Ricciuti, MD PhD, Alessio Cortellini & others. 🌎Collaboration is key to help our patients. Thank you IASLC #LCSM #TeamScience Gustave Roussy Dana-Farber Benjamin Besse Mark Awad shorturl.at/Qo6SU

Congrats to my dear friends and collaborators Mihaela Aldea & Alessio Cortellini on receiving a 2024 IASLC #YIA. Echoing Mihaela Aldea, 🌍 collaboration is key to advancing the field and developing better treatments for #NSCLC.

Just published in Annals of Oncology our study investigating intrapatient variation in PD-L1 & TMB and the impact on outcomes to #immunotherapy in patients with #NSCLC 🧵1/9 Dana-Farber News Dana-Farber's Lowe Center for Thoracic Oncology ESMO - Eur. Oncology IASLC OncoAlert OncLive.com #LCSM annalsofoncology.org/article/S0923-…

New article in press: Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer doi.org/10.1016/j.anno…

Glad to share our last paper just published in Journal of Immunotherapy which investigated the complex relationship between serum proinflammatory cytokine levels, cholesterol metabolism, and clinical outcome in cancer patients undergoing ICIs! journals.lww.com/immunotherapy-…

Tepotinib plus osimertinib in #EGFR+ #NSCLC with #MET amp following progression on first-line osimertinib (INSIGHT 2). OncoAlert ✅ORR 50% (56.6% if MET GCN >10; 42.2% if <10) 💊mPFS 5.6 mo; mOS 17.8 mo 💊On target resistance after combo in 34% pts thelancet.com/journals/lanon…

The August issue of Cancer Discovery is now online! The cover features work by Federica Pecci, Seshiru Nakazawa, Pasi Janne, Mark Awad and colleagues showing that activating point mutations in MET are actionable in lung cancer - read that and more here: aacrjournals.org/cancerdiscover…

Just published in Annals of Oncology ESMO - Eur. Oncology our paper on intrapatient variation in PD-L1 and TMB in #NSCLC authors.elsevier.com/c/1jZPc3I2OQih… Jim Smithy Biagio Ricciuti, MD PhD João Alessi, MD Federica Pecci Mark Awad

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of #LungCancer and Other Malignancies Targetable with MET Inhibitors. bit.ly/4cFiu18 Federica Pecci, Seshiru Nakazawa, Pasi Janne, Mark Awad and colleagues. Dana-Farber

Just out on ESMO Open: #MET exon 14 skipping mutations in #NSCLC #RWD from the Italian biomarker ATLAS database Biomarkers Atlas Great network of colleagues and friends Giulia pasello Francesco Umberto Malapelle Marcello Tiseo sciencedirect.com/science/articl…